The U.S. Supreme Court on Thursday granted requests to keep the abortion medication mifepristone available by mail nationwide [1], [3].
This decision preserves current access to the drug while the legal battle over the Food and Drug Administration's approval of the medication continues. Because mifepristone is a primary component in medication abortions, the ruling prevents a sudden shift in how patients obtain the drug.
The court acted to pause a previous ruling from the U.S. Court of Appeals for the 5th Circuit in New Orleans [1], [5]. That lower-court order, originally issued on May 1, 2026 [4], would have required the medication to be dispensed in person rather than through mail-order pharmacies [2], [3].
Danco Laboratories and GenBioPro were involved in the legal challenges leading to this intervention [1], [2]. The Supreme Court's decision on May 15, 2026 [3], ensures that the status quo remains in place for the immediate future, preventing the 5th Circuit's restrictions from taking effect across the country.
The litigation centers on whether the FDA followed proper procedures when it expanded access to mifepristone. By granting this pause, the justices have ensured that the drug remains accessible via mail while the underlying merits of the case are debated in the legal system [3], [4].
“The U.S. Supreme Court on Thursday granted requests to keep the abortion medication mifepristone available by mail nationwide.”
This ruling prevents an immediate disruption of medication abortion access in the U.S. by blocking a restrictive lower-court mandate. While the Supreme Court has maintained the current distribution method for now, the long-term availability of mifepristone by mail remains uncertain as the court continues to evaluate the legality of the FDA's approval process.
